Literature DB >> 8041155

Macrophage endotoxin tolerance: effect of TNF or endotoxin pretreatment.

M H Li1, S C Seatter, R Manthei, M Bubrick, M A West.   

Abstract

Macrophages pretreated with low-dose endotoxin [lipopolysaccharide (LPS1)] have an altered response to subsequent endotoxin (LPS2) stimulation, a process known as endotoxin tolerance. In this study we investigated whether the LPS1 pretreatment effects were mediated primarily via tumor necrosis factor (TNF alpha). Murine peritoneal macrophages were pretreated in vitro with either TNF alpha or LPS1 and the effects on mediator production in response to a second endotoxin exposure, LPS2, were compared. Mediators in macrophage supernatant were measured using specific bioassays [TNF, interleukin-1 (IL-1), and IL-6] or enzymatic immunoassays [prostaglandin E2 (PGE2) and TNF]. Macrophage production of all mediators was stimulated by endotoxin in the absence of LPS1 pretreatment. Pretreatment with LPS1 completely inhibited LPS2-triggered TNF release whereas preexposure to TNF alpha had no effect. In contrast, LPS1 pretreatment significantly augmented IL-1 and PGE2 release in response to LPS2, whereas pretreatment using either high- or low dose TNF alpha did not. TNF, stimulated by an initial exposure to endotoxin, LPS1, is not solely responsible for the observed alterations in macrophage mediator release following a subsequent endotoxin stimulus (LPS2). Thus, the data suggest that endotoxin tolerance is mediated primarily by factors other than TNF.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8041155     DOI: 10.1006/jsre.1994.1115

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  9 in total

1.  TNF-alpha is a mediator of the anti-inflammatory response in a human neonatal model of the non-septic shock syndrome.

Authors:  S Hassett; P Moynagh; D Reen
Journal:  Pediatr Surg Int       Date:  2006-01       Impact factor: 1.827

2.  Lipopolysaccharide pretreatment protects from renal ischemia/reperfusion injury : possible connection to an interleukin-6-dependent pathway.

Authors:  U Heemann; A Szabo; P Hamar; V Müller; O Witzke; J Lutz; T Philipp
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

3.  Is circulating endotoxin the trigger for the systemic inflammatory response syndrome seen after injury?

Authors:  J L Kelly; C O'Sullivan; M O'Riordain; D O'Riordain; A Lyons; J Doherty; J A Mannick; M L Rodrick
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

4.  Tolerance to shock: an exploration of mechanism.

Authors:  C Mendez; A A Kramer; K F Salhab; G A Valdes; J G Norman; K J Tracey; L C Carey
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

5.  Up-regulation of growth factor independence 1 in endotoxin tolerant macrophages with low secretion of TNF-alpha and IL-6.

Authors:  Min-Fang Zhu; Jing Zhang; Jie-Ming Qu; Hui-Jun Zhang; Shuang-Cheng Zhou; Sheng-Fu Dong; Hong-Ni Jiang; Hanssa Summah
Journal:  Inflamm Res       Date:  2010-04-17       Impact factor: 4.575

6.  Indirect induction of suppressor of cytokine signalling-1 in macrophages stimulated with bacterial lipopolysaccharide: partial role of autocrine/paracrine interferon-alpha/beta.

Authors:  A Crespo; M B Filla; S W Russell; W J Murphy
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

7.  Lipid A-mediated tolerance and cancer therapy.

Authors:  Cheryl E Rockwell; David C Morrison; Nilofer Qureshi
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

8.  Low-dose lipopolysaccharide (LPS) pretreatment of mouse macrophages modulates LPS-dependent interleukin-6 production in vitro.

Authors:  N Hirohashi; D C Morrison
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

9.  HMGB1 and LPS induce distinct patterns of gene expression and activation in neutrophils from patients with sepsis-induced acute lung injury.

Authors:  Eliezer Silva; John Arcaroli; Qianbin He; Daiva Svetkauskaite; Christopher Coldren; Jerry A Nick; Katie Poch; Jong Sung Park; Anirban Banerjee; Edward Abraham
Journal:  Intensive Care Med       Date:  2007-06-21       Impact factor: 17.440

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.